Navigation Links
Well-informed patients key to accepting gene-based drug dosing
Date:4/28/2014

A new study out of Western University (London, Canada) illustrates the need for a lot more education around pharmacogenetics (PGx) the study of how a patient's genes can affect drug reaction and dosage. PGx promises to optimize patient response to therapy, but this is the first study to really investigate how patients perceive this kind of genetic testing, and whether those perceptions differ when it comes to parents and their children. The research, led by Dr. Michael Rieder of Western's Schulich School of Medicine & Dentistry is published in the journal Pediatrics.

"Pharmacogenetic testing has become widely used and gene-based drug dosing is becoming a reality for a number of common health problems. This study confirms what we suspected; Whether or not you're a parent, your degree of acceptability of genetic testing was determined by your knowledge of it. That is to say if you understand what the test is for, and the concept of gene-based drug dosing, you're far more open to it, than if you don't understand it," said Dr. Rieder, a professor in the Departments of Paediatrics, and Physiology and Pharmacology.

The researchers surveyed three groups including: 236 medical students representing those having greater educational exposure to PGx, 1,226 lay parents and 105 lay people without children. A second survey was completed by 229 parents. The surveys didn't use PGx but rather, asked about "DNA testing to guide therapy." The study concluded that the acceptability of PGx testing, either for oneself or one's child, seemed to depend on baseline PGx knowledge, but not on parenthood.

The main concern for all respondents was the need for informed consent. Other findings included:

  • More acceptance for PGx when the disease was severe

  • Strong desire/demand for separate consent for PGx testing

  • More education about PGx needed in medical schools

  • Acceptability of genetic testing didn't differ
    '/>"/>

Contact: Kathy Wallis
kwallis3@uwo.ca
519-661-2111 x81136
University of Western Ontario
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Breast cancer patients place huge emphasis on gene expression profiling test
2. Spinal stimulation helps 4 patients with paraplegia regain voluntary movement
3. Key genetic mutations could be new hope for adrenocortical tumor patients
4. Cause for exaggerated insulin response in subset of bariatric surgery patients identified
5. Faster genetic testing method will likely transform care for patients with breast cancer
6. Certain genetic variants may put bladder cancer patients at increased risk of recurrence
7. How the science of deer hunting can help patients with diabetes
8. Diaphragm pacing in spinal cord injury successful in weaning patients from ventilators
9. Vitamin A used in acne medicines may help autoimmune and transplant patients
10. Gastric banding patients should closely monitor nutrition following surgery
11. Identified a subgroup of schizophrenia patients with motor disorders
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Well-informed patients key to accepting gene-based drug dosing
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
(Date:4/10/2015)... DUBLIN , April 10, 2015 ... the addition of the "Security Competitive Profiles - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to ... solutions to the market, with a company focus on ... solution anticipated. Winning opportunities in the ...
(Date:4/2/2015)... 2015 In the current ... outperforms the strongest competitors, showing outstanding performance in ... system is capable of a throughput of 5.000.000 ... to be ten times faster than most competitors ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... its altitude, ozone can be either friend or foe. ... scientists will now have a better understanding of ozone, its origin ... polluting our atmosphere. Ozone is a colourless, toxic gas named ... In the stratosphere, acting as friend, ...
... wildflower, grows from the Mississippi River to Arizona and ... plant can be seen covering large areas of plains, ... Working to create a new drought-resistant and water-saving ... and Soil Science have introduced ,Raider Amethyst, a new ...
... a page from Nature herself, a team of researchers ... from the atmosphere and place it in the Earth,s ... the new technology does not make the oceans more ... process is a manipulation of the natural weathering of ...
Cached Biology News:Ozone intrusions -- humankind's fault? 2Scientists enhance Mother Nature's carbon handling mechanism 2
(Date:5/1/2015)... 2015 Investor-Edge has initiated ... (NASDAQ: GENE ), Agilent Technologies Inc. (NYSE: ... TMO ), Sequenom Inc. (NASDAQ: SQNM ... Free research report on Genetic Technologies can be ... 30, 2015, the NASDAQ Composite ended at 4,941.42, ...
(Date:4/30/2015)... South Carolina (PRWEB) May 01, 2015 ... system services, is extremely proud to announce that for ... been named as a winner of a Queen’s Award ... success for the design and manufacture of a unique ... is the revolutionary alternative to traditional steam flow measurement. ...
(Date:4/30/2015)... , April 30, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... chemicals, today announced that it has commenced an underwritten public ... to grant the underwriters a 30-day option to purchase ... of common stock offered in the public offering. The ... be no assurance as to whether or when the ...
(Date:4/30/2015)... Budapest, Hungary (PRWEB) April 30, 2015 ... electronic lab notebook with integrated protocols and specimen ... chemistry software solutions and consulting services for life ... the development of Labguru’s newest feature: chemical structure ... deep domain features for biologists, bio-chemists, and more, ...
Breaking Biology Technology:Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2
... York, May 26, 2012 Sanofi ... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today ... trial of SAR236553/REGN727 (Study 1003, NTC01266876) in patients ... subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase ...
... decades, neurologists have known that a diet high in fat ... resist drug therapy. But how the diet worked, and why, ... York Times Magazine called it "Epilepsy,s Big, Fat Miracle." ... School have proposed an answer, linking resistance to seizures to ...
... growth of crystals, do nanoparticles act as "artificial atoms" ... structures? This is the contention of a major but ... researchers at the U.S. Department of Energy (DOE),s Lawrence ... and point the way to energy devices of the ...
Cached Biology Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 2Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 3Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 4Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 5Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 6Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 7Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 8Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet 9Reverse engineering epilepsy's 'miracle' diet 2Reverse engineering epilepsy's 'miracle' diet 3Nanoparticles seen as artificial atoms 2Nanoparticles seen as artificial atoms 3
TXNL2 Antibody...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Request Info...
Goat polyclonal to SART1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: GSSKKHRGEKEAA, corresponding to N terminal amino acids 2-14 of Human SART1. Entrez Gene ID: 909...
Biology Products: